Koeth Laura M, Jacobs Michael R, Bajaksouzian Saralee, Zilles Anne, Lin Gengrong, Appelbaum Peter C
Laboratory Specialists, Inc., 1651 A Crossings Parkway, Westlake, OH 44145, USA.
Int J Antimicrob Agents. 2002 Jan;19(1):33-7. doi: 10.1016/s0924-8579(01)00431-9.
This study was undertaken to assess the in vitro activity of gemifloxacin, five other fluoroquinolone antimicrobial agents (ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin and ofloxacin) and other non-quinolone comparator agents (ampicillin, erythromycin, clindamycin, doxycycline, penicillin and trimethoprim/sulphamethoxazole) against Streptococcus pneumoniae collected in the United States. Susceptibility testing of 550 S. pneumoniae, 290 Haemophilus influenzae and 205 Moraxella catarrhalis showed that 38.2% of pneumococci were penicillin nonsusceptible, while 26.2 and 95.6% of H. influenzae and M. catarrhalis, respectively, produced beta-lactamase. Overall new fluoroquinolones were the most active agents. The in vitro activity (based on MIC90 in mg/l) of the six fluoroquinolones was gemifloxacin>moxifloxacin>gatifloxacin>levofloxacin>ciprofloxacin and ofloxacin.
本研究旨在评估吉米沙星、其他五种氟喹诺酮类抗菌药物(环丙沙星、加替沙星、左氧氟沙星、莫西沙星和氧氟沙星)以及其他非喹诺酮类对照药物(氨苄西林、红霉素、克林霉素、多西环素、青霉素和甲氧苄啶/磺胺甲恶唑)对在美国收集的肺炎链球菌的体外活性。对550株肺炎链球菌、290株流感嗜血杆菌和205株卡他莫拉菌进行的药敏试验表明,38.2%的肺炎球菌对青霉素不敏感,而流感嗜血杆菌和卡他莫拉菌分别有26.2%和95.6%产生β-内酰胺酶。总体而言,新型氟喹诺酮类药物是活性最强的药物。六种氟喹诺酮类药物的体外活性(基于以mg/l为单位的MIC90)为吉米沙星>莫西沙星>加替沙星>左氧氟沙星>环丙沙星和氧氟沙星。